Overview
Med tech firm's fiscal Q2 net sales beat analysts' expectations, driven by Med Tech growth
Adjusted net income for fiscal Q2 beat estimates
Company achieved FDA approvals for Mechanical Thrombectomy portfolio
Company raised FY 2026 guidance for net sales and adjusted EBITDA
Outlook
AngioDynamics raises FY 2026 net sales guidance to $312 - $314 mln
Company expects FY 2026 adjusted EBITDA between $8.0 mln and $10.0 mln
AngioDynamics maintains positive cash flow guidance for FY 2026
Result Drivers
MED TECH GROWTH - Med Tech segment saw a 13% increase in net sales, driven by platforms like Auryon and NanoKnife
REGULATORY MILESTONES - Achieved FDA approvals for APEX-Return study and PAVE clinical study, expanding Mechanical Thrombectomy portfolio
GROSS MARGIN IMPROVEMENT - Gross margin increased due to product mix shift towards Med Tech and manufacturing initiatives
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | $79.43 mln | $76.30 mln (3 Analysts) |
Q2 Adjusted EPS | $0.00 | -$0.10 (3 Analysts) | |
Q2 Adjusted Net Income | Beat | -$100,000 | -$4.19 mln (3 Analysts) |
Q2 Net Income | -$6.40 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AngioDynamics Inc is $17.00, about 28.5% above its January 5 closing price of $13.23
Press Release: ID:nBw3MhKHpa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
